Background Epidermal growth factor receptor inhibitors (EGFRI) produce various
dermatologic side effects in the majority of patients, and guidelines are crucial for the …

Answer questions and earn CME/CNE Advances in genomics and molecular biology have
identified aberrant proteins in cancer cells that are attractive targets for cancer therapy …

There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …

Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …

Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …

Inhibition of the epidermal growth factor receptor (EGFR) is an established treatment that
extends patient survival across a variety of tumor types. EGFR inhibitors fall into two main …

Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an
essential treatment for many advance‐stage epithelial cancers. These agents have the …

Purpose As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety
of dermatologic adverse events (dAEs), the purpose of this study was to develop an …

Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …

Background. Agents targeting the epidermal growth factor receptor (EGFR) are amongst the
most extensively used of the targeted agents in the therapy of some of the most common …